- Details
- Rana McKay discusses the NePtune study, investigating PARP inhibitors as a neoadjuvant treatment for prostate cancer patients with BRCA1/2 mutations. This study, inspired by the success of PARP inhibitors in metastatic settings and neoadjuvant successes in other cancers, aims to address the aggressive nature of BRCA-mutated prostate cancer earlier in the disease course. With a multi-institutional...
|
- Details
- Alicia Morgans interviews Alan Bryce about his session on radiopharmaceutical therapies for mCRPC with bone metastases, focusing on the decision-making between radium-223 and lutetium-177. Dr. Bryce explains the session aimed at practical clinical decision-making, emphasizing the underlying science of radiopharmaceuticals, including the distinctions between alpha and beta emitters and their target...
|
- Details
- Alicia Morgans interviews Maha Hussain about the BRCAAWAY trial, a phase two study exploring the efficacy of combining abiraterone and olaparib for patients with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM mutations. Highlighting the journey from the inception of the trial to its execution, Hussain delves into the rigorous selection criteria and the strategic des...
|
- Details
- Zach Klaassen and Daniel George discuss the highlights from ASCO GU 2024 including the BRCAAway trial, a study focusing on the combination of PARP inhibitors and novel hormonal agents for treating metastatic castration-resistant prostate cancer. Dr. George explains the trial's innovative design, which explored the efficacy of abiraterone and olaparib, both separately and in combination, in patient...
|
- Details
- Jacob Orme and Emmanuel Antonarakis discuss their study on the use of PARP inhibitors in metastatic prostate cancer patients with BRCA2 and SPOP mutations. Dr. Antonarakis shares the study's genesis, rooted in his clinical observation of exceptional responses to PARP inhibitors in patients with these mutations. The study, involving 131 patients across 13 international sites, reveals that patients...
|
- Details
- Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...
|
- Details
- Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...
|
- Details
- Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal dosages, shows potential in treating prostate cancer, a field historically resistant to immune therapy. Dr. Morris emphasizes AMG 509's ability to reduce bony and visceral diseases, including liver disease, with m...
|
- Details
- Zach Klaassen engages with Colin Pritchard in a detailed discussion about genomic testing in prostate cancer. They emphasize the importance of genomic testing, particularly in advanced prostate cancer, for treatment decisions and family counseling. Dr. Pritchard highlights the clinical utility of both germline and somatic testing, especially in metastatic cases, and discusses the timing and types...
|
- Details
- Zach Klaassen speaks with Abhishek Srivastava about the significance of germline and genomic testing in advanced prostate cancer. Dr. Srivastava elaborates on his recent publication, which aims to improve the penetration of such testing in urology, particularly in community practices. He emphasizes the importance of cascade testing for identifying actionable mutations and influencing treatment opt...
|
